Jaka jest cena za AB Science S.A. (AB)

Cena za AB Science S.A. (AB) wynosi $0.82200553

Jaka jest kapitalizacja rynkowa dla AB Science S.A. (AB)

Kapitalizacja rynkowa dla AB Science S.A. (AB) wynosi $60.21M

AB Science S.A. (AB) Marża Operacyjna

AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors for applications in both human and animal health. Its primary drug candidate, masitinib, a tyrosine kinase inhibitor, is currently undergoing late-stage (Phase III) clinical investigations for a range of serious conditions including prostate cancer, pancreatic cancer, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer's disease, severe asthma, and mastocytosis. Additionally, masitinib is being evaluated in Phase II clinical trials for the treatment of Covid-19. The company's pipeline also features AB8939, a synthetic microtubule destabilizer aimed at treating acute myeloid leukemia, and AB20001, which is in Phase 2 trials to assess the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients experiencing moderate to severe COVID-19. Masitinib is sold under the brand name Masivet in the European market. AB Science S.A. was founded in 2001 and is based in Paris, France.

Rok	Marża operacyjna	Zmień
Za mało danych dla podanych dat.

Rok

Marża operacyjna

Zmień

Za mało danych dla podanych dat.

Firma	Marża operacyjna	Różnica w marży operacyjnej	Kraj
MERCK Kommanditgesellschaft auf Aktien MER.SW	0.00%	-	DE
Merck KGaA MRK.DE	0.00%	-	DE
Takeda Pharmaceutical Company Limited 4502.T	0.00%	-	JP
Galderma Group AG GALD.SW	0.00%	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	22.93%	-	IN

Firma

Marża operacyjna

Różnica w marży operacyjnej

Kraj